Fatty liver disease (MASLD/MASH): who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PPAR 1
• AMPK 0
• GLP-1 7
• SGLT2 5
• NRF2 1
• SIRT1 0
• PNPLA3 6
• NLRP3 1
• mTOR 0
• AKT 0
• PI3K 0
• STAT3 0
• TLR4 0
• MAPK 0
• STING 0
• JNK 0
• TP53 0
• PINK1 0
• TNF 2
• HIF-1 0
• JAK 0
• GIP 1
• TFEB 0
• YAP 0
• CTNNB1 0
• ERK 0
• COX-2 0
• HSP90 0
• PTEN 0
• STK11 0
• APOE 0
• FTO 0
• HMGB1 0
• IL-6 0
• KEAP1 0
• PCSK9 0
• DPP-4 0
• GPX4 0
• VEGF 0
• FGFR 0
• IL-17 0
• PDGFR 0
• BDNF 0
• IL-1 0
• METTL3 0
• PKM2 0
• TREM2 0
• ACE2 0
• EGFR 0
• FAK 0
• IDH 0
• MDM2 0
• PARP 0
• PD-1 0
• RANKL 1
• ABL1 0
• ALK 0
• BCL-2 0
• CD38 0
• CD40 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 26+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  GLP-1 RA on Liver OMICS in MASLD

  NCT06982378· Medical College of Wisconsin· Updated 13 Jul 2026

  “no grant approved”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Eli Lilly and Company· Source

• Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)

  NCT07718126· West China Hospital· Source

• CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry

  NCT07567378· JULIO GRANADOS MONTIEL· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 24
• Organoids 17
• Mendelian Randomization Analysis 45
• CRISPR-Cas Systems 3
• Gene Expression Profiling 105
• Sequence Analysis, RNA 10
• Whole Genome Sequencing 3
• Exome Sequencing 2
• Proteomics 65
• Metabolomics 103
• Mass Spectrometry 10
• Flow Cytometry 3
• Immunohistochemistry 16
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 102
• Machine Learning 103
• Deep Learning 14
• Cohort Studies 172
• Genome-Wide Association Study 48

• Antihypertensive Treatment and Risk of Metabolic Associated Fatty Liver Disease: A Drug-Target Mendelian Randomization.

  Hypertension, Sept 2026

• Liver-eye axis in metabolic syndrome: integrated evidence from mendelian randomization, single-cell sequencing, and clinical sample validation.

  Front Endocrinol (Lausanne), Sept 2026

• Multi-omics dissection of MASLD reveals divergent pathways to systemic diseases and targets for prevention.

  Metabolism, Aug 2026

• Plasma metabolic signatures of healthy dietary patterns and risk of metabolic dysfunction-associated steatotic liver disease and cirrhosis.

  Hepatol Int, Jul 2026

• Causal relationship between plasma branched-chain amino acids levels and nonalcoholic fatty liver disease: a bidirectional Mendelian randomization study.

  Exp Gerontol, Jun 2026

• The Reciprocal Risk Relationship of Dental Caries with NAFLD and Liver Fibrosis: Combined Evidence from the NHANES Study and Mendelian Randomization Analysis.

  Oral Health Prev Dent, Jun 2026

• Integrative Single-Cell Transcriptomic, Mendelian Randomization and In Silico Perturbation Analyses Prioritize MUC20 as a Candidate Gene Associated with Osteoporosis and Metabolic Dysfunction-Associated Steatotic Liver Disease in the Liver-Bone Axis.

  Int J Mol Sci, Jun 2026

• Insulin resistance drives GGT elevation in MASLD with diabetes: evidence from clinical cohorts, mendelian randomization and functional genomics.

  Nutr Diabetes, Jun 2026

• Genetics of MASLD: a diabetes perspective.

  Diabetologia, Jun 2026

• Risk factors for atherosclerotic plaque formation in MASLD patients: insights from cross-sectional and Mendelian randomization analyses.

  Nutr Metab Cardiovasc Dis, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.